Vimarsana
Biggest News Aggregation in the World

Vector Engineering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vector Engineering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vector Engineering Today - Breaking & Trending Today

Global Viral Vector Production Market Reprot 2023: Clinical - Vimarsana News

Global Viral Vector Production Market Reprot 2023: Clinical

Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The

Tectonic Metals : Attracts Leading Exploration and Mining Experts to Form Technical Advisory Committee - Vimarsana News

Tectonic Metals : Attracts Leading Exploration and Mining Experts to Form Technical Advisory Committee

VANCOUVER, B.C., August 16, 2023 - Tectonic Metals Inc. TECT: TSX-V; TETOF: OTCQB; T15B: FSE) , a mineral exploration company employing a rigorous up-front approach to addressing project risk,... -Today at 07:11 am- MarketScreener

Tectonic Metals Attracts Leading Exploration and Mining Experts to ... - Vimarsana News

Tectonic Metals Attracts Leading Exploration and Mining Experts to ...

Tectonic Metals Attracts Leading Exploration and Mining Experts to ...

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results - Vimarsana News

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12

Source: yahoo.com
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results - Vimarsana News

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

14.03.2023 - -   Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 -   Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and ...